A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

Author： Chow Laura   Eckhardt S.   O’Bryant Cindy   Schultz Mary   Morrow Mark   Grolnic Stacy   Basche Michele   Gore Lia  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.62, Iss.4, 2008-09, pp. : 631-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

By Plummer Ruth   Madi Ayman   Jeffels Melinda   Richly Heike   Nokay Bahar   Rubin Stephen   Ball Howard   Weller Steve   Botbyl Jeffrey   Gibson Diana   Scheulen Max  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 93-101

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

By Wong Nan Soon   Meadows Kellen L.   Rosen Lee S.   Adjei Alex A.   Kaufmann Scott H.   Morse Michael A.   Petros William P.   Zhu Yali   Statkevich Paul   Cutler David L.   Meyers Michael L.   Hurwitz Herbert I.  

Cancer Investigation, Vol. 29, Iss. 9, 2011-10 ,pp. : 617-625

Informa Healthcare

Access to resources Recommend Favorite

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

By Awada A.   Eskens F.A.L.M.   Piccart M.   Cutler D.L.   van der Gaast A.   Bleiberg H.   Wanders J.   Faber M.N.   Statkevich P.   Fumoleau P.   Verweij J.   for the EORTC Early Clinical Studies Group  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2272-2278

Elsevier

Access to resources Recommend Favorite

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

By Schelman William   Morgan-Meadows Sherry   Bailey Howard   Holen Kyle   Thomas James   Eickhoff Jens   Brandon Heidi   Oliver Kate   Alberti Dona   Wilding George  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 727-733

Springer Publishing Company

Access to resources Recommend Favorite